|Bid||87.60 x 1200|
|Ask||87.64 x 800|
|Day's Range||86.71 - 88.58|
|52 Week Range||79.13 - 106.74|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||119.13|
SAN RAFAEL, Calif. , May 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Robert Baffi , Ph.D., Executive Vice President, Technical Operations, will participate ...
Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Sell with a D+ rating by TheStreet's Quant Ratings.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
BioMarin Pharmaceutical Inc. is set to announce results of its medicine, Valrox, that will show how durable the next-generation drug is three years after dosing. The update has been seen across Wall Street as the next key value driver for shares and could spur the stock to either rise or fall as much as 25 percent, according to Wedbush. Investors have become increasingly wary of how much the medicine’s benefit will decline compared to two-year results.
Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.
The markets have been rocked this week by escalating trade tensions between the U.S. and China as well as potentially new tariffs on the horizon. As such, valrox, if efficacy is durable, has the potential to be the largest product for BioMarin.
SAN RAFAEL, Calif. , May 8, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Bank ...
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $4.13 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Netflix and Google employees are now in Silicon Valley's $200K club. The typical Googler earned $246,804 last year — up 25 percent year-over-year. At Netflix, the median employee made $202,335 last year after getting a 10 percent pay boost over 2017.
First Enzyme Substitution Therapy Approved in Europe to Treat the Underlying Cause of PKU in Patients Aged 16 Years or Older at Doses up to 60 mg Treatment Lowers Phe and Suggestive of Beneficial Effects ...
The biotechnology space is an exciting one with incredible potential for investors. One strategy that many have found success with in the biotech investing space is making moves around catalysts. This involves looking for companies with data readouts, PDUFA dates, and other upcoming releases that will likely move the needle for the stock.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
The San Rafael, California-based company said it had a loss of 32 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, came to 14 cents per share. The results beat Wall ...
- Total Revenues Top $400 million in the Quarter - Full-year 2019 Total BioMarin Revenue Guidance of Between $1.68 billion to $1.75 billion Reaffirmed - As of March 31, 2019, 414 U.S. Commercial Patients ...
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at ...
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...
When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.
Biotech stocks are on track to extend their losses, bucking the positive broader market sentiment. The week saw Achaogen Inc (NASDAQ: AKAO ) filing for Chapter 11 bankruptcy and negative clinical readouts ...